Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
Naproxcinod; Nitronaproxen; HCT 3012; AZD 3582; Naproxen-n-butyl nitrate; 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
CAS Number:
Naproxcinod, a nitro compound, has been found to be a nitric oxide donor as well as a cyclooxygenase inhibitor that was once studied aginast duchenne muscular dystrophy.
Molecular Weight:
Molecular Formula:
Quality Standard:
In-house standard
Canonical SMILES:
COX | Others
Chemical Structure

Related COX Products

(CAS: 864082-48-4)

GSK466317A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor.

CAS 53963-43-2 Ginsenoside F1

Ginsenoside F1
(CAS: 53963-43-2)

Ginsenoside F1, a metabolite of ginsenoside Rg1, which is used as an aldose reductase inhibitor and my exert anti-inflammatory and immunomodulatory activity.

CAS 80382-23-6 Loxoprofen Sodium

Loxoprofen Sodium
(CAS: 80382-23-6)

CAS 1421227-52-2 WS3

(CAS: 1421227-52-2)

WS3 induces proliferation of the mouse β cell line R7T1 with EC50 of 0.074 μM.

(CAS: 352308-27-1)

CP-5484 is a synthetic bio-active chemical with potent anti-MRSA activity and low acute toxicity.

CAS 1509-34-8 L-Allo-isoleucine

(CAS: 1509-34-8)

L-Allo-isoleucine, an amino acid compound, has been found to be probably significant in the study of modulating of blood sugar.

CAS 5466-77-3 Octinoxate

(CAS: 5466-77-3)

Octinoxate is an organic compound that is an ingredient in some sunscreens and lip balms used in sunscreens and other cosmetics

CAS 603148-36-3 Azeliragon

(CAS: 603148-36-3)

Azeliragon is a potent and orally active RAGE inhibitor as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).

CAS 188817-13-2 SC-560

(CAS: 188817-13-2)

SC-560 is an orally active and highly selective cyclooxygenase-1 (COX-1) inhibitor with IC50= 0.009 μM for COX-1, and 6.3 μM for COX-2. SC-560 also significantl...

CAS 169590-42-5 Celecoxib

(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

(CAS: 1620692-60-5)

KPU-300, a diketopiperazine derivative, has been found to be an antimicrotubule agent and exhibit cytotoxicity against HT-29 cells. IC50: 7.0 nM.

UK 35493
(CAS: 113213-52-8)

This molecular is a biochemical.

CAS 71125-38-7 Meloxicam

(CAS: 71125-38-7)

Meloxicam (Mobic) is a nonsteroidal anti-inflammatory agent with analgesic and fever reducer effects.

CAS 36740-73-5 Flumizole

(CAS: 36740-73-5)

Flumizole is a non-steroidal anti-inflammatory drug (NSAID) that acts via inhibition of the enzyme cyclooxygenase (COX).

CAS 169590-41-4 Deracoxib

(CAS: 169590-41-4)

Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class. Deracoxin is a selective cyclooxygenase-2 (COX-2) inhibitor used in the treatmen...

Cgp 13143
(CAS: 75919-69-6)

Cgp 13143 is a bio-active chemical,but no detailed information has been published yet.

Canfosfamide Hydrochloride
(CAS: 439943-59-6)

Canfosfamide is a modified glutathione analogue as a small-molecule antineoplastic compound with potential antineoplastic activity. Canfosfamide is selectively ...

CAS 114030-44-3 Dexpemedolac

(CAS: 114030-44-3)

Dexpemedolac is a bio-active chemical compound,but no detailed information is published.

CAS 110623-73-9 Epmedin B

Epmedin B
(CAS: 110623-73-9)

Epimedin B, a flavonoids natural product extracted from Herbal Epimedium, has been studied to have potential antiosteoporotic effect.

CAS 1617-53-4 Amentoflavone

(CAS: 1617-53-4)

Amentoflavone, which comes from the seed of Ginkgo biloba L, can interact with many other medications by being a potent inhibitor of CYP3A4 and CYP2C9, which ar...

Reference Reading

1.AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells.
Berndt G1, Grosser N, Hoogstraate J, Schröder H. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. Epub 2005 Mar 29.
AZD3582 [4-(nitrooxy)-butyl-(2S)-2-(6-methoxy-2-naphthyl)-propanoate] is a COX-inhibiting nitric oxide donator (CINOD). Incubation of human endothelial cells (derived from umbilical cord) with AZD3582 (10-100muM) led to increased expression of heme oxygenase (HO)-1 mRNA and protein. Heme oxygenase-1 (HO-1) is a crucial mediator of antioxidant and tissue-protective actions. In contrast, naproxen (a non-selective NSAID) and rofecoxib (a selective inhibitor of COX-2), did not affect HO-1 expression. Pre-treating endothelial cells with AZD3582 at concentrations that were effective at inducing HO-1 also reduced NADPH-dependent production of oxygen radicals. Antioxidant activity in the endothelial cells persisted after AZD3582 had been washed out from the incubation medium. When added exogenously to the cells at low micromolar concentrations, the HO-1 metabolite, bilirubin, virtually abolished NADPH-dependent oxidative stress. AZD3582-induced blockade of free-radical formation was reversed in the presence of the HO-1 inhibitor, tin protoporphyrin-IX (SnPP).
2.The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers.
Jonzon B1, Bjarnason I, Hawkey C, Jones J, Goddard A, Fagerholm U, Karlsson P. Inflammopharmacology. 2003;11(4):437-44.
COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs in development for the treatment of acute and chronic pain. They comprise a COX-inhibiting moiety linked to a nitric-oxide-donating component and are designed to provide an innovative mechanism of action of balanced COX inhibition and controlled nitric oxide donation. Through these pathways, CINODs should provide analgesic and anti-inflammatory efficacy, while offering gastrointestinal safety through the tissue-protective effects of nitric oxide donation. AZD3582 [4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)propanoate] is the first agent in the CINOD class to enter extensive clinical development. Pre-clinical studies demonstrate that AZD3582 has a superior gastrointestinal safety profile to naproxen, while demonstrating analgesic and anti-inflammatory efficacy. In healthy human volunteers, AZD3582 caused little gastrointestinal damage compared with equimolar doses of naproxen.
3.Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo.
Adding LC1, Agvald P, Andersson LI, Jonzon B, Hoogstraate J, Gustafsson LE. Br J Pharmacol. 2005 Jul;145(5):679-87.
1. AZD3582 [4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)propanoate] is a COX-inhibiting nitric oxide donor that inhibits COX-1 and COX-2. It is as effective as naproxen in models of pain and inflammation, but causes less gastroduodenal damage. Nitric oxide (NO) is generated from AZD3582 in vitro, and this study sought to show that the drug donates NO in vivo. 2. In anaesthetised male New Zealand white rabbits, the endogenous NO concentration in exhaled air was reduced by N(G)-nitro-L-arginine methyl ester (L-NAME) (30 mg kg(- 1) i.v.) from 33.5+/-1.0 ppb (mean+/-s.e.m.; n=6 per group) to 3.0+/-1.0 ppb, while increasing blood pressure and reducing heart rate. AZD3582 (0.2, 0.6, 2.0 or 6.0 micromol kg(- 1) min(- 1)) given 30 min after L-NAME increased the concentration of NO in exhaled air (P<0.05), decreased blood pressure and increased heart rate in a dose-dependent manner versus L-NAME control values. The peak mean NO concentration obtained was 44+/-8.
4.Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Huledal G1, Jonzon B, Malmenäs M, Hedman A, Andersson LI, Odlind B, Brater DC. Clin Pharmacol Ther. 2005 May;77(5):437-50.
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) and can thereby reduce renal function, especially with respect to solute excretion and renal perfusion. AZD3582 [4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)propanoate] is a COX-inhibiting nitric oxide donator. Donation of nitric oxide by AZD3582 could preserve blood flow and thereby counteract the deleterious effects of COX inhibition in the gastrointestinal tract and possibly in other organ systems, including the kidney. The aim of this single-dose study was to assess the hypothesis that AZD3582 would not adversely affect renal function compared with NSAIDs.